Please ensure Javascript is enabled for purposes of website accessibility

Why Provention Bio Stock Crashed Today

By Keith Speights - May 28, 2021 at 4:18PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

An FDA advisory committee vote was a lot closer than anticipated.

What happened

Shares of Provention Bio (PRVB -3.91%) crashed 28.8% as of the market close on Friday. The huge decline came after a U.S. Food and Drug Administration (FDA) advisory committee voted 10-7 in favor of recommending approval of teplizumab in delaying type 1 diabetes.

So what

Investors were clearly expecting a more lopsided vote for teplizumab after the FDA's briefing documents seemed quite positive about Provention's clinical data. Those documents stated that the company's TN-10 clinical study "successfully demonstrated the treatment effect of teplizumab in delaying T1D diagnosis." 

A person touching an end of a scale so that one side with a green figure shaped like a person is lower than the other side with a red figure shaped like a person.

Image source: Getty Images.

However, the FDA's Endocrinologic and Metabolic Drugs Advisory Committee wasn't as convinced about the experimental drug. Some of the committee members expressed reservations about the small size of the pivotal study conducted by Provention. They were also concerned that patients weren't followed after being diagnosed with type 1 diabetes.

It's possible that the relatively narrow vote increases the chances that teplizumab won't win FDA approval. However, the agency usually goes along with advisory committee recommendations.

Now what

What's next for the biotech stock? The FDA is scheduled to announce its decision on approval for teplizumab by July 2. 

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Provention Bio, Inc. Stock Quote
Provention Bio, Inc.
PRVB
$5.40 (-3.91%) $0.22

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
403%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.